Rita Ruijter

1.0k total citations
14 papers, 841 citations indexed

About

Rita Ruijter is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Rita Ruijter has authored 14 papers receiving a total of 841 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 6 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Rita Ruijter's work include Colorectal Cancer Treatments and Studies (4 papers), Lung Cancer Treatments and Mutations (4 papers) and HER2/EGFR in Cancer Research (3 papers). Rita Ruijter is often cited by papers focused on Colorectal Cancer Treatments and Studies (4 papers), Lung Cancer Treatments and Mutations (4 papers) and HER2/EGFR in Cancer Research (3 papers). Rita Ruijter collaborates with scholars based in Netherlands, United States and United Kingdom. Rita Ruijter's co-authors include Giuseppe Giaccone, Herbert M. Pinedo, Hans van Vliet, M. Roelvink, Yukio Ando, Marlies Peters, Cornelis J. A. Punt, Jos H. Beijnen, Alfons J.M. van den Eertwegh and Rik J. Scheper and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

Rita Ruijter

14 papers receiving 818 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rita Ruijter Netherlands 11 422 332 212 98 92 14 841
Cécile Pagès France 19 232 0.5× 794 2.4× 302 1.4× 46 0.5× 190 2.1× 53 1.1k
Uri Sagman Canada 11 177 0.4× 461 1.4× 381 1.8× 49 0.5× 231 2.5× 19 905
Kristin Padavic United States 9 178 0.4× 205 0.6× 394 1.9× 28 0.3× 68 0.7× 10 612
Faezeh Khodadadi Iran 4 265 0.6× 470 1.4× 197 0.9× 33 0.3× 135 1.5× 6 749
Yavar Shiravand Italy 7 285 0.7× 493 1.5× 214 1.0× 19 0.2× 147 1.6× 9 844
Brian Belmontes United States 13 169 0.4× 421 1.3× 322 1.5× 15 0.2× 203 2.2× 22 757
Robert P. Whitehead United States 14 176 0.4× 527 1.6× 285 1.3× 19 0.2× 189 2.1× 38 824
Yanina Jansen Belgium 15 192 0.5× 595 1.8× 345 1.6× 33 0.3× 156 1.7× 48 887
Jun Ji China 15 115 0.3× 202 0.6× 285 1.3× 46 0.5× 70 0.8× 29 673
Jacob J. Orme United States 14 251 0.6× 227 0.7× 241 1.1× 16 0.2× 201 2.2× 74 744

Countries citing papers authored by Rita Ruijter

Since Specialization
Citations

This map shows the geographic impact of Rita Ruijter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rita Ruijter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rita Ruijter more than expected).

Fields of papers citing papers by Rita Ruijter

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rita Ruijter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rita Ruijter. The network helps show where Rita Ruijter may publish in the future.

Co-authorship network of co-authors of Rita Ruijter

This figure shows the co-authorship network connecting the top 25 collaborators of Rita Ruijter. A scholar is included among the top collaborators of Rita Ruijter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rita Ruijter. Rita Ruijter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Rovithi, Maria, Richard J. Honeywell, Albert J. ten Tije, et al.. (2018). Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors. Journal of Clinical Oncology. 37(5). 411–418. 13 indexed citations
2.
Zweeden, Annette A. van, C.J. van Groeningen, Richard J. Honeywell, et al.. (2018). Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer. Cancer Chemotherapy and Pharmacology. 82(1). 39–48. 11 indexed citations
3.
Labots, Mariëtte, Johannes C. van der Mijn, Henk Dekker, et al.. (2018). Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study. The Oncologist. 23(10). 1135–e118. 3 indexed citations
4.
Rovithi, Maria, Mariëtte Labots, Richard J. Honeywell, et al.. (2017). A phase 1/2 study of intermittent, high dose sunitinib in patients with advanced solid tumors.. Journal of Clinical Oncology. 35(15_suppl). 2591–2591. 1 indexed citations
5.
Kaye, Stan B., Steinar Aamdal, Richard D. Jones, et al.. (2012). Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours. British Journal of Cancer. 106(11). 1728–1734. 29 indexed citations
6.
Schöffski, Patrick, Herlinde Dumez, Rita Ruijter, et al.. (2011). Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies. Cancer Chemotherapy and Pharmacology. 68(6). 1397–1403. 26 indexed citations
7.
Kuenen, Bart C., Petronella O. Witteveen, Rita Ruijter, et al.. (2010). A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 16(6). 1915–1923. 66 indexed citations
8.
Giaccone, Giuseppe, Arun Rajan, Rita Ruijter, et al.. (2009). Imatinib Mesylate in Patients with WHO B3 Thymomas and Thymic Carcinomas. Journal of Thoracic Oncology. 4(10). 1270–1273. 85 indexed citations
9.
Kuenen, Bart C., Els O. Witteveen, Rita Ruijter, et al.. (2006). A phase I study of IMC-11F8, a fully human anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumors. Interim results. Journal of Clinical Oncology. 24(18_suppl). 3024–3024. 7 indexed citations
10.
Boven, Epie, Marjan J. Westerman, C.J. van Groeningen, et al.. (2005). Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule. British Journal of Cancer. 92(9). 1636–1643. 14 indexed citations
11.
Kuenen, Bart C., Giuseppe Giaccone, Rita Ruijter, et al.. (2005). Dose-Finding Study of the Multitargeted Tyrosine Kinase Inhibitor SU6668 in Patients with Advanced Malignancies. Clinical Cancer Research. 11(17). 6240–6246. 34 indexed citations
12.
13.
Kuenen, Bart C., Lee S. Rosen, Egbert F. Smit, et al.. (2002). Dose-Finding and Pharmacokinetic Study of Cisplatin, Gemcitabine, and SU5416 in Patients With Solid Tumors. Journal of Clinical Oncology. 20(6). 1657–1667. 113 indexed citations
14.
Giaccone, Giuseppe, Cornelis J. A. Punt, Yukio Ando, et al.. (2002). A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.. PubMed. 8(12). 3702–9. 426 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cécile Pagès Breakdown of academic impact, for papers by Uri Sagman Breakdown of academic impact, for papers by Kristin Padavic Breakdown of academic impact, for papers by Faezeh Khodadadi Breakdown of academic impact, for papers by Yavar Shiravand Breakdown of academic impact, for papers by Brian Belmontes Breakdown of academic impact, for papers by Robert P. Whitehead Breakdown of academic impact, for papers by Yanina Jansen Breakdown of academic impact, for papers by Jun Ji Breakdown of academic impact, for papers by Jacob J. Orme
Rankless by CCL
2026